5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Other O
ERAs O
cause O
hepatotoxicity O
and O
liver O
failure O
. O

Obtain O
baseline O
liver O
enzymes O
and O
monitor O
as O
clinically O
indicated O
( O
5.3 O
) O
. O

* O
Decreases O
in O
hemoglobin O
( O
5.4 O
) O
. O

* O
Pulmonary O
edema O
in O
patients O
with O
pulmonary O
veno-occlusive O
disease O
. O

If O
confirmed O
, O
discontinue O
treatment O
( O
5.5 O
) O
. O

* O
Decreases O
in O
sperm O
count O
have O
been O
observed O
in O
patients O
taking O
ERAs O
( O
5.6 O
) O
. O

5.1 O
Embryo B-OSE_Labeled_AE
- I-OSE_Labeled_AE
fetal I-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
OPSUMIT O
may O
cause O
fetal B-OSE_Labeled_AE
harm I-OSE_Labeled_AE
when O
administered O
during O
pregnancy B-Not_AE_Candidate
and O
is O
contraindicated O
for O
use O
in O
females O
who O
are O
pregnant B-Not_AE_Candidate
. O

In O
females O
of O
reproductive O
potential O
, O
exclude O
pregnancy B-Not_AE_Candidate
prior O
to O
initiation O
of O
therapy O
, O
ensure O
use O
of O
acceptable O
contraceptive O
methods O
and O
obtain O
monthly O
pregnancy O
tests O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
and O
Use O
in O
Specific O
Populations O
( O
8.1 O
, O
8.6 O
) O
] O
. O

OPSUMIT O
is O
available O
for O
females O
through O
the O
OPSUMIT O
REMS O
Program O
, O
a O
restricted O
distribution O
program O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

5.2 O
OPSUMIT O
REMS O
Program O
For O
all O
females O
, O
OPSUMIT O
is O
available O
only O
through O
a O
restricted O
program O
called O
the O
OPSUMIT O
REMS O
Program O
, O
because O
of O
the O
risk O
of O
embryo B-OSE_Labeled_AE
- I-OSE_Labeled_AE
fetal I-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
[ O
see O
Contraindications O
( O
4.1 O
) O
, O
Warnings O
and O
Precautions O
( O
5.1 O
) O
, O
and O
Use O
in O
Specific O
Populations O
( O
8.1 O
, O
8.6 O
) O
] O
. O

Notable O
requirements O
of O
the O
OPSUMIT O
REMS O
Program O
include O
the O
following O
: O
* O
Prescribers O
must O
be O
certified O
with O
the O
program O
by O
enrolling O
and O
completing O
training O
. O

* O
All O
females O
, O
regardless O
of O
reproductive O
potential O
, O
must O
enroll O
in O
the O
OPSUMIT O
REMS O
Program O
prior O
to O
initiating O
OPSUMIT O
. O

Male O
patients O
are O
not O
enrolled O
in O
the O
REMS O
. O

* O
Females O
of O
reproductive O
potential O
must O
comply O
with O
the O
pregnancy O
testing O
and O
contraception O
requirements O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.6 O
) O
] O
. O

* O
Pharmacies O
must O
be O
certified O
with O
the O
program O
and O
must O
only O
dispense O
to O
patients O
who O
are O
authorized O
to O
receive O
OPSUMIT O
. O

Further O
information O
is O
available O
at O
www.OPSUMITREMS.com O
or O
1-866-228-3546 O
. O

Information O
on O
OPSUMIT O
certified O
pharmacies O
or O
wholesale O
distributors O
is O
available O
through O
Actelion O
Pathways O
at O
1-866-228-3546 O
. O

5.3 O
Hepatotoxicity O
Other O
ERAs O
have O
caused O
elevations B-NonOSE_AE
of I-NonOSE_AE
aminotransferases I-NonOSE_AE
, O
hepatotoxicity B-NonOSE_AE
, O
and O
liver B-NonOSE_AE
failure I-NonOSE_AE
. O

The O
incidence O
of O
elevated B-NonOSE_AE
aminotransferases I-NonOSE_AE
in O
the O
study O
of O
OPSUMIT O
in O
PAH B-Not_AE_Candidate
is O
shown O
in O
Table O
1 O
. O

Table O
1 O
Incidence O
of O
Elevated B-OSE_Labeled_AE
Aminotransferases I-OSE_Labeled_AE
in O
the O
SERAPHIN O
Study O
OPSUMIT O
10 O
mg O
( O
N=242 O
) O
Placebo O
( O
N=249 O
) O
> I-OSE_Labeled_AE
3 O
* O
ULN O
3.4 O
% O
4.5 O
% O
> O
8 I-OSE_Labeled_AE
* I-OSE_Labeled_AE
ULN I-OSE_Labeled_AE
2.1 O
% O
0.4 O
% O
In O
the O
placebo-controlled O
study O
of O
OPSUMIT O
, O
discontinuations O
for O
hepatic B-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
events I-OSE_Labeled_AE
were O
3.3 O
% O
in O
the O
OPSUMIT O
10 O
mg O
group O
vs O
. O
1.6 O
% O
for O
placebo O
. O

Obtain O
liver O
enzyme O
tests O
prior O
to O
initiation O
of O
OPSUMIT O
and O
repeat O
during O
treatment O
as O
clinically O
indicated O
. O

Advise O
patients O
to O
report O
symptoms O
suggesting O
hepatic B-NonOSE_AE
injury I-NonOSE_AE
( O
nausea B-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
right B-NonOSE_AE
upper I-NonOSE_AE
quadrant I-NonOSE_AE
pain I-NonOSE_AE
, O
fatigue B-NonOSE_AE
, O
anorexia B-NonOSE_AE
, O
jaundice B-NonOSE_AE
, O
dark B-NonOSE_AE
urine I-NonOSE_AE
, O
fever B-NonOSE_AE
, O
or O
itching B-NonOSE_AE
) O
. O

If O
clinically O
relevant O
aminotransferase B-NonOSE_AE
elevations I-NonOSE_AE
occur O
, O
or O
if O
elevations O
are O
accompanied O
by O
an O
increase B-NonOSE_AE
in I-NonOSE_AE
bilirubin I-NonOSE_AE
> I-NonOSE_AE
2 I-NonOSE_AE
* I-NonOSE_AE
ULN I-NonOSE_AE
, O
or O
by O
clinical O
symptoms O
of O
hepatotoxicity B-NonOSE_AE
, O
discontinue O
OPSUMIT O
. O

Consider O
re-initiation O
of O
OPSUMIT O
when O
hepatic O
enzyme O
levels O
normalize O
in O
patients O
who O
have O
not O
experienced O
clinical O
symptoms O
of O
hepatotoxicity B-NonOSE_AE
. O

5.4 O
Hemoglobin O
Decrease O
Decreases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
concentration I-OSE_Labeled_AE
and O
hematocrit O
have O
occurred O
following O
administration O
of O
other O
ERAs O
and O
were O
observed O
in O
clinical O
studies O
with O
OPSUMIT O
. O

These O
decreases O
occurred O
early O
and O
stabilized O
thereafter O
. O

In O
the O
placebo-controlled O
study O
of O
OPSUMIT O
in O
PAH B-Not_AE_Candidate
, O
OPSUMIT O
10 O
mg O
caused O
a O
mean O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
from O
baseline O
to O
up O
to O
18 O
months O
of O
about O
1.0 O
g/dL O
compared O
to O
no O
change O
in O
the O
placebo O
group O
. O

A O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
to O
below O
10.0 O
g/dL O
was O
reported O
in O
8.7 O
% O
of O
the O
OPSUMIT O
10 O
mg O
group O
and O
in O
3.4 O
% O
of O
the O
placebo O
group O
. O

Decreases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
seldom O
require O
transfusion O
. O

Initiation O
of O
OPSUMIT O
is O
not O
recommended O
in O
patients O
with O
severe B-Not_AE_Candidate
anemia I-Not_AE_Candidate
. O

Measure O
hemoglobin O
prior O
to O
initiation O
of O
treatment O
and O
repeat O
during O
treatment O
as O
clinically O
indicated O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.5 O
Pulmonary O
Edema O
with O
Pulmonary O
Veno-occlusive O
Disease O
( O
PVOD O
) O
Should O
signs O
of O
pulmonary B-NonOSE_AE
edema I-NonOSE_AE
occur O
, O
consider O
the O
possibility O
of O
associated O
PVOD B-OSE_Labeled_AE
. O

If O
confirmed O
, O
discontinue O
OPSUMIT O
. O

5.6 O
Decreased O
Sperm O
Counts O
Other O
ERAs O
have O
caused O
adverse B-NonOSE_AE
effects I-NonOSE_AE
on I-NonOSE_AE
spermatogenesis I-NonOSE_AE
. O

Counsel O
men O
about O
potential O
effects O
on O
fertility O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.6 O
) O
and O
Nonclinical O
Toxicology O
( O
13.1 O
) O
] O
. O

